kneat.com, inc. (TSXV: KSI) is pleased to announce that it has closed its previously announced short form prospectus offering, including the full exercise of the over-allotment option. As such, a total of 6,037,500 common shares of the Company were sold at a price of $1.05 per common share for aggregate gross proceeds of $6,339,375. The Offering was completed by a syndicate of underwriters led by Cormark Securities Inc., and including Echelon Wealth Partners Inc. and Mackie Research Capital Corporation.

The Company also completed the non-brokered private placement of 2,074,437 common shares of the Company at the Issue Price for aggregate gross proceeds of $2,178,159. The common shares issued pursuant to the Private Placement are subject to a statutory four month hold period in accordance with applicable securities laws.

In connection with the Offering, the Company paid the Underwriters cash fees totaling $255,362.52 and issued 219,393 broker warrants, with each broker warrant exercisable into a common share at an exercise price of $1.05 per share for a period of 24 months.  In connection with the Private Placement, the Company paid cash finders fees totaling $130,689.52 and issued 124,466 broker warrants, with each broker warrant exercisable into a common share at an exercise price of $1.05 per share for a period of 24 months.

The Company intends to use the net proceeds of the Offering and the Private Placement for growth initiatives, working capital and general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements.

About Kneat

Kneat develops and markets the next generation Kneat Gx software platform. Multiple business processes can be configured on the platform from equipment to computer system validation, through to quality document management. Kneat’s software allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes worldwide. Customer case studies are reporting productivity improvements in excess of 100% and a higher data integrity and compliance standard.